To Test a Payer/Treatment Agency Intervention to Increase Use of

Status Completed

Clinical Trial Summary

A team of researchers from the University of Wisconsin-Madison College of Engineering and Oregon Health & Science University will test whether clinician training and the use of organizational change strategies are sufficient for disseminating an evidence-based practice (EBP), or if changes to both organizational systems and payer policy results in greater EBP use. Demonstrating the role of payment policy as a driver in the adoption of evidence-based practices could provide a contribution to dissemination and implementation science. This study will employ an intervention that was developed through the Robert Wood Johnson Foundation-funded Advancing Recovery (AR) program. In AR, payer/treatment organization partnerships in 12 states collaborated to remove systemic barriers to the adoption of EBPs such as medication-assisted treatment for substance abuse disorders. The resulting "AR Framework" of payer and organizational change strategies will be tested against its ability to increase the use of the addiction medication buprenorphine as compared to organizational change strategies alone. Buprenorphine is an EBP for treating people addicted to heroin or opioid-based pain medications for non-medical use. Buprenorphine has experienced low adoption rates and is not a standard part of addiction treatment. In Ohio, the location of the study, deaths to due to accidental overdoses of opioids has increased by 304% over the past decade and surpassed auto accidents as the leading cause of accidental deaths in 2006. Ohio was selected for the study because of the public health significance of opioid abuse and because each county in Ohio acts as a stand-alone payer, offering 48 unique eligible payer environments. This trial will develop a deeper understanding of the role payers and treatment organizations play in implementing and disseminating EBPs and will focus on the public health issue of rising opioid abuse.

Clinical Trial Description

Buprenorphine (EBP) use data will be collected from November, 2012 to May, 2016 through administrative databases located at the state of Ohio. Participants will be followed for the duration of Buprenorphine use that is an average of 5-7 months. Organizational and Payer data will be collected from January, 2013 to January, 2015. The data from the study will be analyzed and reported during January 2015 to February 2017. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01702142
Study type	Observational
Source	University of Wisconsin, Madison
Contact
Status	Completed
Phase
Start date	March 2012
Completion date	February 28, 2018

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03576768` - QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt	N/A
Completed	`NCT04110626` - Realistic Evaluation of Expériences Animées, a School-based Intervention in Nouvelle Aquitaine
Completed	`NCT03007940` - Using NIATx Strategies to Implement Integrated Services in Routine Care	N/A
Not yet recruiting	`NCT04030858` - The INFINITE Study: A Prospective Investigation of a Nutrient-dense Diet in Early Addiction Recovery	N/A
Completed	`NCT03347643` - The Effectiveness of tDCS on Internet Game Addiction	Phase 2
Active, not recruiting	`NCT02836080` - Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT)	N/A
Completed	`NCT03221985` - ESM Pilot: Mobile Phones and Psychology	N/A
Completed	`NCT02556060` - Lamotrigine for Ketamine Dependence Trial	Phase 2/Phase 3
Completed	`NCT02812810` - Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) Low-frequency on Craving in Smoking Dependence	N/A
Completed	`NCT01531153` - Cognitive Enhancement as a Target for Cocaine Pharmacotherapy	N/A
Recruiting	`NCT05976646` - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion	Phase 1/Phase 2
Completed	`NCT04409106` - The Turkish Version of the Parental Smartphone Use Management Scale (PSUMS)
Not yet recruiting	`NCT06459609` - Effect of Protein Supplementation on Craving in Subjects Hospitalised for Addiction Treatment	N/A
Recruiting	`NCT05595759` - Violence Against Women in Patients With Alcohol Substance Addiction Training	N/A
Completed	`NCT04099173` - A Brief Mindfulness-Based Intervention for Suicidal Ideation	N/A
Recruiting	`NCT04959643` - Systematic Screening for Viral Hepatitis B and C at the PASS Consultation of the Montpellier University Hospital
Completed	`NCT04133688` - Mobile App in Addiction	N/A
Recruiting	`NCT04063267` - Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder	Phase 2
Completed	`NCT05114577` - Recovery Sleepers: A Pilot Study of a Sleep Health Intervention for College Students in Recovery	N/A
Terminated	`NCT02671240` - Prognosis of Behavioral Addiction in Parkinson's Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms